Amgen CEO's compensation jumped to $13.6 million in 2012

Compensation for five of Amgen’s top executives fell 9.57 percent in 2012. Their combined earnings were $43.9 million compared with $48.6 million in 2011.

CEO Robert Bradway replaced Kevin Sharer at the helm when Sharer retired May 23. In a proxy statement released Monday, the Thousand Oaks-based biotech company reported Bradway’s compensation rose to nearly $13.6 million last year from $7.1 million in 2011.

The 50-year-old’s compensation jumped primarily because of stock awards, which were $8.6 million in 2012 compared with $3.1 million in 2011.

Bradway’s base salary in 2012 was $1.26 million, up from $1 million in 2011. He got a $3.3 million cash bonus compared with $1.9 million in 2011. His additional compensation included $65,009 for personal use of company aircraft, $4,256 for personal use of a company car and driver, $17,805 for personal expenses on business travel and $2,564 for expenses related to guests accompanying him on business travel. He also received nearly $314,000 in retirement plan contributions.

Sharer, who remained on as chairman of the board through the end of 2012, received $9.1 million in total compensation last year, about half of the $18.9 million he earned in 2011.

Amgen is allowing Sharer retirement benefits that include keeping a leased office space, a secretary, travel support and information technology through the end of 2017 at a cost of $270,721, according to public filings.

Sharer’s $9 million compensation package for 2012 included that $270,721 as well as $261,712 for personal use of company aircraft, $20,346 for personal use of a company car and driver, $23,346 for personal expenses on business travel and $15,040 for expenses related to guests accompanying him on that travel. His perquisites totaled more than $600,000. The company also added $751,414 to his retirement plans.

Total compensation includes salary, bonuses, awarded stock and option values, an increase in retirement benefits and other incentives.